Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ablaze Pharma Acquires China Rights to Targeted Radiotherapy Drug for Liver Cancers

publication date: Mar 31, 2023

Shanghai Ablaze Pharma in-licensed China rights to a first-in-class novel peptide drug candidate aimed at treating liver cancer from San Diego’s RayzeBio. The candidate targets GPC3, which is expressed only by the liver. In preclinical tests, the GPC3 candidate showed tumor specific uptake and anti-tumor efficacy in preclinical models. Ablaze develops Targeted Radiotherapy drugs for China cancer patients and operates as RayzeBio’s development/commercialization arm in China. Ken Song, MD, is President and CEO at RayzeBio and Chairman of Ablaze, although the two companies are considered separate. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital